Viatris agrees to buy Pacira BioSciences for $36.50 a share in cash, valuing deal at $1.65 billion
Bitget2026/10/08 11:53Viatris agreed to buy Pacira BioSciences for USD 36.50 per share in cash, valuing the equity at about USD 1.65 billion. Pacira brings EXPAREL and ZILRETTA, two marketed, patent-protected non-opioid pain therapies in the U.S. Pacira generated about USD 746 million revenue and USD 177 million adjusted EBITDA in the 12 months ended June 30, 2026. Viatris expects to fund the deal mainly with excess cash, using short-term borrowings for the remainder. Closing is targeted by end-2026; Pacira would become a wholly owned Viatris unit and be delisted from Nasdaq. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on October 08, 2026, and is solely responsible for the information contained therein.
- Viatris agreed to buy Pacira BioSciences for USD 36.50 per share in cash, valuing the equity at about USD 1.65 billion.
- Pacira brings EXPAREL and ZILRETTA, two marketed, patent-protected non-opioid pain therapies in the U.S.
- Pacira generated about USD 746 million revenue and USD 177 million adjusted EBITDA in the 12 months ended June 30, 2026.
- Viatris expects to fund the deal mainly with excess cash, using short-term borrowings for the remainder.
- Closing is targeted by end-2026; Pacira would become a wholly owned Viatris unit and be delisted from Nasdaq.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI transformation dividends strengthen profit growth logic! SAP (SAP.US) upgraded to "Overweight" by JPMorgan, target price raised to 275 euros
JPMorgan has upgraded its rating on SAP from "Neutral" to "Overweight" in its latest report, raising the target price from 175 euros in December 2027 to 275 euros in December 2028, implying an upside potential of approximately 30%.
Nymex US crude oil futures main contract at $89.99 per barrel, down 0.92% intraday
Crypto prices
More
